- Integra LifeSciences Holdings press release ( NASDAQ: IART ): Q2 GAAP EPS of $0.54 beats by $0.09 .
- Revenue of $398M (+2.1% Y/Y) beats by $2.62M .
- Six-month revenues for 2022 were $774 million and increased 3.3% on a reported basis and 5.2% on an organic basis compared to the prior year.
- The Company is tightening its previous full-year 2022 organic growth guidance of 3.8% to 5.2% to an updated range of 4.0% to 5.2%, reflecting better than expected first half performance.
- Full-year 2022 reported revenue guidance is updated to a range of $1,557 million to $1,575 million representing reported growth of 1.0% to 2.1%, inclusive of the planned sale of the TWC business and an updated foreign currency outlook. Adjusted earnings per share guidance range is updated accordingly to $3.21 to $3.29.
For further details see:
Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M